Download MendeleyStructure-Based Design of an Iminoheterocyclic beta-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central A beta in Nonhuman Primates.
Mandal, M., Wu, Y., Misiaszek, J., Li, G., Buevich, A., Caldwell, J.P., Liu, X., Mazzola, R.D., Orth, P., Strickland, C., Voigt, J., Wang, H., Zhu, Z., Chen, X., Grzelak, M., Hyde, L.A., Kuvelkar, R., Leach, P.T., Terracina, G., Zhang, L., Zhang, Q., Michener, M.S., Smith, B., Cox, K., Grotz, D., Favreau, L., Mitra, K., Kazakevich, I., McKittrick, B.A., Greenlee, W., Kennedy, M.E., Parker, E.M., Cumming, J.N., Stamford, A.W.(2016) J Med Chem 59: 3231-3248
- PubMed: 26937601
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01995
- Primary Citation of Related Structures:
5HD0, 5HDU, 5HDV, 5HDX, 5HDZ, 5HE4, 5HE5, 5HE7 - PubMed Abstract:
We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold. Employing structure-based design, truncation of the cyanophenyl group of 6 that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued ...
